Advertisement

Topics

Novartis' Tafinlar + Mekinist Combo Wins FDA Okay for BRAF V600E-Mutant NSCLC

05:20 EDT 23 Jun 2017 | Genetic Engineering News

FDA approved Novartis’ BRAF inhibitor Tafinlar® (dabrafenib) and MEK1/2 inhibitor Mekinist® (trametinib) as combination therapy for patients with BRAF V600E mutated metastatic non-small cell lung cancer (NSCLC). Novartis said the clearance marks the first in the U.S. for a targeted therapy specifically for metastatic NSCLC with BRAF V600E mutations.The drug combination was cleared by the EC in March for the treating patients with BRAF V600 advanced mutation-positive NSCLC.  The treatment combination is approved for use alongside Thermo Fisher Scientific's companion diagnostic Oncomine™ Dx Target Test to identify eligible patients with BRAF V600-mutated tumors. The Oncomine Dx Target Test was separately granted FDA 510(k) clearance today . NSCLC patients with the BRAF V600E mutation have typically responded less well to standard chemotherapy, commented Bruno Strigini, Novartis Oncology CEO. "Today's approval of the Tafinlar + Mekinist combination validates our expertise in tumor biology, which enabled us to develop the ...

Original Article: Novartis' Tafinlar + Mekinist Combo Wins FDA Okay for BRAF V600E-Mutant NSCLC

NEXT ARTICLE

More From BioPortfolio on "Novartis' Tafinlar + Mekinist Combo Wins FDA Okay for BRAF V600E-Mutant NSCLC"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...

Novartis
Novartis is the fourth largest pharmaceutical company in the world, based on annual sales, which are exceeded $36,000m in 2009. Founded in 1996, Novartis focuses of four main areas; pharmaceuticals, vaccines & diagnostics, generic medicines and biosi...

Gilotrif (afatinib)
GILOTRIF (afatinib) is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L8...